No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Masimo Sleep™, a New Wellness Solution That Allows Users to Better Understand Their Sleep Quality

Editor: What To Know

  • Based on our expertise in monitoring the physiological status of hundreds of millions of patients each year, Masimo Sleep significantly expands consumers' ability to make healthier decisions, at home, by equipping them with what we believe is the best solution for this need.
  • The user wears a lightweight sensor (for up to ten nights per sensor), while the Sleep app collects the user's data using clinically proven Masimo SET® pulse oximetry to track changes in key vital signs during sleep.
  • Masimo Sleep is fueled by the same expertise in signal processing and sensor development that drives the Masimo hospital products used by leading institutions to monitor over 200 million patients a year.

June 19, 2020

Masimo announced today a new health and wellness home monitoring solution, Masimo Sleep™, designed to help consumers better understand the quality of their sleep.

Masimo Sleep is fueled by the same expertise in signal processing and sensor development that drives the Masimo hospital products used by leading institutions to monitor over 200 million patients a year.1

Masimo Sleep, a wearable sleep quality solution based on clinically proven vital signs technology, is unlike any other sleep management solution available to consumers. Masimo Sleep analyzes your data to provide truly personalized multi-dimensional insight into your sleep health—empowering you with actionable guidance to help you make healthier lifestyle choices that improve your sleep.

The user wears a lightweight sensor (for up to ten nights per sensor), while the Sleep app collects the user’s data using clinically proven Masimo SET® pulse oximetry to track changes in key vital signs during sleep. By analyzing oxygenation, heart rate, and respiratory rate overnight, Masimo Sleep can provide guidance to help users better understand, for example, why they may snore or wake up tired, and recommend ways for the user to improve the quality of their sleep. Other at home products look at proxies for healthy sleep, like how often users roll over, or listen to the sound of users’ breathing and snoring, rather than their vital signs. Masimo Sleep helps people to better understand their physiological status overnight—from the comfort of their own bed.

Joe Kiani, Founder, and CEO of Masimo, said, “We are delighted to unveil Masimo Sleep as part of our line of direct-to-consumer solutions, which also includes the MightySat® fingertip pulse oximeter. Based on our expertise in monitoring the physiological status of hundreds of millions of patients each year, Masimo Sleep significantly expands consumers’ ability to make healthier decisions, at home, by equipping them with what we believe is the best solution for this need.”

Masimo Sleep is not FDA 510(k) cleared. It is available as a general wellness product. Pre-order here.


References

  1. Estimate: Masimo data on file.
  2. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at https://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
  3. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  4. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  5. Taenzer AH et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
  6. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  7. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  8. https://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy